OBJECTIVE: IL-1β is a master switch of inflammation and plays an important role in the pathogenesis of vascular disease. During early atherosclerosis development, it is not clearly understood how oxidized low density lipoprotein (oxLDL)induced signaling pathways control NLRP3 inflammasome activation and produce IL-1β and promote foam cells formation. METHODS: The study used THP-1 macrophage as cell model. Western blot quantified the oxLDL-induced NLRP3 inflammasome related proteins. The FACS detected the expression of SR-A and CD36 receptors on the cells, and caspase-1 activation in the cells. The DCFH-DA assayed the reactive oxygen species (ROS). Oil red O staining techniques examined the intracellular lipid droplet. RESULTS: The OxLDL remarkably increased not only IL-1β mRNA transcription and pro-IL-1β protein synthesis but also IL-1β secretion in human macrophages. The activation of the NLRP3 inflammasome depended on oxLDL-induced generation of ROS, potassium efflux and cathepsin B activity. The OxLDL-induced ROS production that mediates IL-1β maturation mainly depended on the scavenger receptor of CD36 but not SR-A. The secreted IL-1β served as an autocrine function for promoting macrophage foam cells formation. CONCLUSIONS: These findings suggest that oxLDL-induced NLRP3 inflammasome activation mainly depends on CD36 involved in the progression of atherosclerosis by promoting oxLDL-mediated inflammation and foam cell formation.
OBJECTIVE: IL-1β is a master switch of inflammation and plays an important role in the pathogenesis of vascular disease. During early atherosclerosis development, it is not clearly understood how oxidized low density lipoprotein (oxLDL)induced signaling pathways control NLRP3 inflammasome activation and produce IL-1β and promote foam cells formation. METHODS: The study used THP-1 macrophage as cell model. Western blot quantified the oxLDL-induced NLRP3 inflammasome related proteins. The FACS detected the expression of SR-A and CD36 receptors on the cells, and caspase-1 activation in the cells. The DCFH-DA assayed the reactive oxygen species (ROS). Oil red O staining techniques examined the intracellular lipid droplet. RESULTS: The OxLDL remarkably increased not only IL-1β mRNA transcription and pro-IL-1β protein synthesis but also IL-1β secretion in human macrophages. The activation of the NLRP3 inflammasome depended on oxLDL-induced generation of ROS, potassium efflux and cathepsin B activity. The OxLDL-induced ROS production that mediates IL-1β maturation mainly depended on the scavenger receptor of CD36 but not SR-A. The secreted IL-1β served as an autocrine function for promoting macrophage foam cells formation. CONCLUSIONS: These findings suggest that oxLDL-induced NLRP3 inflammasome activation mainly depends on CD36 involved in the progression of atherosclerosis by promoting oxLDL-mediated inflammation and foam cell formation.
Authors: Weerapan Khovidhunkit; Arthur H Moser; Judy K Shigenaga; Carl Grunfeld; Kenneth R Feingold Journal: J Lipid Res Date: 2003-06-01 Impact factor: 5.922
Authors: Sai Kuchibhotla; Difernando Vanegas; David J Kennedy; Ella Guy; George Nimako; Richard E Morton; Maria Febbraio Journal: Cardiovasc Res Date: 2007-12-07 Impact factor: 10.787
Authors: Cameron R Stewart; Lynda M Stuart; Kim Wilkinson; Janine M van Gils; Jiusheng Deng; Annett Halle; Katey J Rayner; Laurent Boyer; Ruiqin Zhong; William A Frazier; Adam Lacy-Hulbert; Joseph El Khoury; Douglas T Golenbock; Kathryn J Moore Journal: Nat Immunol Date: 2009-12-27 Impact factor: 25.606
Authors: Charan V Devarakonda; Flavia E Pereira; Jonathan D Smith; Linda H Shapiro; Mallika Ghosh Journal: Atherosclerosis Date: 2019-06-13 Impact factor: 5.162
Authors: Andrzej Witkowski; Gary K L Chan; Jennifer C Boatz; Nancy J Li; Ayuka P Inoue; Jaclyn C Wong; Patrick C A van der Wel; Giorgio Cavigiolio Journal: FASEB J Date: 2018-01-17 Impact factor: 5.191
Authors: Arwa Younis; Dana Eskenazi; Ronen Goldkorn; Jonathan Leor; Nili Naftali-Shani; Enrique Z Fisman; Alexander Tenenbaum; Ilan Goldenberg; Robert Klempfner Journal: Cardiovasc Diabetol Date: 2017-05-22 Impact factor: 9.951
Authors: Jillian P Rhoads; John R Lukens; Ashley J Wilhelm; Jared L Moore; Yanice Mendez-Fernandez; Thirumala-Devi Kanneganti; Amy S Major Journal: J Immunol Date: 2017-01-27 Impact factor: 5.422
Authors: Ana Carolina P Souza; Alexander V Bocharov; Irina N Baranova; Tatyana G Vishnyakova; Yuning G Huang; Kenneth J Wilkins; Xuzhen Hu; Jonathan M Street; Alejandro Alvarez-Prats; Adam E Mullick; Amy P Patterson; Alan T Remaley; Thomas L Eggerman; Peter S T Yuen; Robert A Star Journal: Kidney Int Date: 2016-04 Impact factor: 10.612